rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRDL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
      Oct 1Yahoo FinanceCRDL
      Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone

      Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCRDL
      Cardiol expands phase III trial enrollment to 150 patients
      Sep 23Investing.comCRDL
      Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

      Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailCRDL
      Cardiol Therapeutics at H.C. Wainwright conference: trial nears finish
      Sep 14Investing.comCRDL
      Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL)

      Cardiol Therapeutics is a binary, catalyst-driven biotech, with its investment case hinging on CardiolRx’s Phase III MAVERIC trial. See more on CRDL stock here.

      Sep 12Seeking AlphaCRDL
      Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus After OSC Review

      Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailCRDL
      Cardiol Therapeutics files $150 million shelf prospectus
      Sep 10Investing.comCRDL
      Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?
      Sep 10Yahoo FinanceCRDL
      Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

      Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the

      Sep 10Yahoo FinanceCRDL
      Stocks in play: Cardiol Therapeutics Inc.

      Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailCRDL
      Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

      Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailCRDL
      B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential
      Aug 26Investing.comCRDLRILYRILYGRILYLRILYNRILYTRILYZ
      Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

      Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

      Aug 25Yahoo FinanceCRDL

      This is the newest page. Registered accounts read further back.